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1. Course for the students (9h – 11h)  
 
“Voyage[s] through the thymus, the small ‘brain’ of the adaptive immune system” 
 
Structure and summary of the lesson: 
• Evolution of the concepts about thymus physiology. 
• T-cell differentiation in the thymus. 
• Intrathymic programming of central immunological self-tolerance. 
• A primary thymus defect in the development of organ-specific autoimmunity. 
• Clinical evaluation of thymopoiesis. 
• Thymus involvement in immunosenescence. 
 
Reference 
The Development and Survival of Lymphocytes. 
In: Janeway’s Immunobiology, 7th edition (2008), Garland Science, pp. 257-320. 
 
 
2. Seminar (11h30 – 12h30) 
 
“Thymus and Type 1 diabetes: Where are we now?” 
 
Our studies have demonstrated that the thymus programs central self-tolerance to neuroendocrine functions 
through transcription of neuroendocrine-related genes in thymic epithelial cells (TECs). However, thymic 
neuroendocrine precursors are not secreted but processed as the source of neuroendocrine self-antigens that are 
presented by thymic proteins of the major histocompatibility complex (MHC). This process, highly specific of the 
thymus, has allowed an integrated and harmonious coevolution of the neuroendocrine and immune systems 
when recombination-activating genes and the subsequent adaptive immune response have emerged in 
cartilaginous fishes some 450 millions years ago. 
All the members of the insulin gene family are expressed in murine TECs under the control of AutoImmune 
Regulator (AIRE) according a precise hierarchy: Igf2 >Igf1>Ins2>Ins1. Igf2 transcription is defective in TECs of 
autoimmune diabetes-prone BB rats, and tolerance to insulin is severely impaired in Igf2-/- mice as well as in Igf2-
loxP/Foxn1-cre mice with Igf2 deletion targeted in TECs. In addition, the diabetogenic coxsackievirus B4 (CV-B4) 
is able to persistently infect human and murine TECs and to inhibit Igf2 transcription and IGF-2 synthesis in a 
murine medullary TEC line (collaboration with D. Hober, Laboratory of Virology, CHRU and University of Lille 2, 
France). 
These studies show that: 1° IGF-2 is the dominant tolerogenic precursor of the family and mediates cross-
tolerance to insulin; 2° A thymus dysfunction plays a crucial role in the development of the diabetogenic 
autoimmune response; and 3° Thymic infection by CV-B4 is implicated in type 1 diabetes (T1D) pathogenesis. 
Most probably due to its very low level of expression in the thymus, the protein insulin is highly immunogenic and 
is the primary autoantigen tackled in T1D. On the basis of the tolerogenic properties of IGF-2, we are currently 
working on the development of a negative/tolerogenic self-vaccine against T1D. 
 
(Our studies have been and/or are supported by Fund Leon Fredericq at Liege University Hospital, University of Liege, Wallonia, FRS and FRIA of 
Belgium, and by the European FP6 Integrated Project Euro-Thymaide.) 
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